Extracorporeal adsorption therapy: a method to improve targeted radiation delivered by radiometal-labeled monoclonal antibodies.

Publication Type:

Journal Article

Authors:

Nemecek, Eneida R; Green, Damian J; Fisher, Darrell R; Pagel, John M; Lin, Yukang; Gopal, Ajay K; Durack, Lawrence D; Rajendran, Joseph G; Wilbur, D Scott; Nilsson, Rune; Sandberg, Bengt; Press, Oliver W

Source:

Cancer biotherapy & radiopharmaceuticals, Volume 23, Issue 2, p.181-91 (2008)

Keywords:

2008, Animals, Antibodies, Monoclonal, Antibodies, Monoclonal, Murine-Derived, Antibody Development Core Facility, Biologics Production Core Facility, Center-Authored Paper, Clinical Research Division, Drug Delivery Systems, Flow Cytometry Core Facility, Immunoconjugates, Lutetium, Macaca, Male, Radioisotopes, Radiometry, Research Trials Office Core Facility - Biostatistics Service, Shared Resources, Specialized Pathology Core Facility

Abstract:

Radiolabeled anti-CD20 antibodies have demonstrated impressive efficacy in the treatment of relapsed non-Hodgkin's lymphoma. However, the amount of radiation that can be delivered to eradicate the malignancy is limited by toxicity to normal organs. We examined an "extracorporeal adsorption therapy" (ECAT) method to remove circulating unbound radioimmunoconjugate and improve the ratios of radiation delivered to B-cells in a macaque model.